Oppenheimer analyst Justin Kim lowered the firm’s price target on Zura Bio (ZURA) to $19 from $20 and keeps an Outperform rating on the shares after the company released year-end financial and operational results for 2024. Year-ending cash of $176.5M is anticipated to support operations through 2027, however this does not include funds for major clinical work beyond systemic sclerosis and HS trials, the firm notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: